Targinta’s CEO to BioStock: “Strong interest in ADCs in 2023”

During 2023, we have witnessed several significant business deals involving Antibody-drug conjugates (ADC), both in preclinical and clinical phase. This signals a continued strong interest in the field. AbbVie made a multi-billion dollar acquisition of ImmunoGen, Merck entered into a development agreement with Daiichi, and Pfizer acquired Seagen for a record amount. Evy Lundgren-Åkerlund, CEO of ADC developer Targinta, shares her analysis. 

Read the full article at biostock.se:

https://www.biostock.se/en/2024/01/targintas-ceo-strong-interest-in-adcs-in-2023/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se